为所有人提供三重疗法:基因组无关的方法来改善AML中的HMA + VEN?
William Nicol1, Andrew H Wei1,2
1Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia.
Hematology. American Society of Hematology. Education Program
|December 5, 2025
概括
患有急性髓性白血病 (AML) 的老年患者经常通过低甲基化剂 (HMA) 加上维尼托克拉克斯 (Ven) 疗法实现缓解. 新的三重组合正在开发中,以克服耐药性并改善AML治疗中的存活率.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 联合低甲基化剂 (HMA) 加上venetoclax (Ven) 治疗是急性髓性白血病 (AML) 的老年患者的标准治疗方法.
- 大多数患者通过HMA-Ven疗法实现临床缓解,但耐药性和缓解时间有限仍然是重大挑战.
- 开发新的三重组合对于克服耐药性机制和改善AML的长期结果至关重要.
研究的目的:
- 探索开发用于急性髓性白血病 (AML) 治疗的新型三重组合.
- 为了研究规避对低甲基化剂 (HMA) 加上venetoclax (Ven) 治疗的耐药性的策略.
- 提高老年AML患者的缓解寿命和整体存活率.
主要方法:
- 将HMA-Ven与针对关键瘤性途径的新型药物结合在一起的基因组学不可知论方法.
- 研究影响白血病细胞存活,增殖,新陈代谢或分化的药物.
- 在AML异质性和毒性背景下评估潜在的三重组合.
主要成果:
- 在老年AML患者中,HMA-Ven疗法在实现缓解方面表现出有效性.
- 三重组合的开发旨在解决抗性的机制,并提高响应的耐用性.
- 挑战包括针对性治疗的竞争,AML异质性和潜在的添加剂毒性.
结论:
- 新的三重组合有望改善老年AML患者的治疗结果.
- 克服耐药性和延长缓解是推动AML治疗的关键目标.
- 仔细考虑AML生物学和潜在的毒性对于成功的三胞胎发育至关重要.
相关概念视频
02:50Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K